New eczema drug shows promise in early safety trial
NCT ID NCT05114889
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 33 times
Summary
This early-stage study tested a new medicine called BSI-045B in 54 healthy adults and people with eczema (atopic dermatitis). The main goal was to check if the drug is safe and tolerable. Researchers also looked at how the drug works in the body and whether it can improve eczema symptoms. This is a first step to see if the drug is worth testing in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Scientia Clinical Research
Randwick, New South Wales, Australia
Conditions
Explore the condition pages connected to this study.